Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Rekha Sangwan, Remya Rajan, Pintu Kumar Mandal
European Journal of Medicinal Chemistry (2018) Vol. 158, pp. 620-706
Closed Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Indole: A privileged scaffold for the design of anti-cancer agents
Yichao Wan, Yuanhua Li, Chunxing Yan, et al.
European Journal of Medicinal Chemistry (2019) Vol. 183, pp. 111691-111691
Closed Access | Times Cited: 383
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Маргарита Е. Неганова, С. Г. Клочков, Yulia Aleksandrova, et al.
Seminars in Cancer Biology (2020) Vol. 83, pp. 452-471
Closed Access | Times Cited: 124
Next-generation of selective histone deacetylase inhibitors
Feifei Yang, Na Zhao, Di Ge, et al.
RSC Advances (2019) Vol. 9, Iss. 34, pp. 19571-19583
Open Access | Times Cited: 112
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Suvankar Banerjee, Nilanjan Adhikari, Sk. Abdul Amin, et al.
European Journal of Medicinal Chemistry (2018) Vol. 164, pp. 214-240
Closed Access | Times Cited: 97
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets
Antonino Lauria, Gabriele La Monica, Alessia Bono, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113555-113555
Closed Access | Times Cited: 65
Design and Synthesis of New Quinoxaline Derivatives as Potential Histone Deacetylase Inhibitors Targeting Hepatocellular Carcinoma: In Silico, In Vitro, and SAR Studies
Chao Ma, Mohammed S. Taghour, Amany Belal, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 58
A comprehensive overview of β-carbolines and its derivatives as anticancer agents
Bo Luo, Xinqiang Song
European Journal of Medicinal Chemistry (2021) Vol. 224, pp. 113688-113688
Closed Access | Times Cited: 57
Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment
Xianbo Wu, Jie Wang, Qi Liang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113116-113116
Open Access | Times Cited: 38
Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator
Dipanjan Karati, Swarupananda Mukherjee, Souvik Roy
Medical Oncology (2024) Vol. 41, Iss. 4
Closed Access | Times Cited: 11
Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents
Vincent Montero, Marc Montana, Manon Carré, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116360-116360
Open Access | Times Cited: 8
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Yan Li, Fang Wang, Xiaoxue Chen, et al.
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 3, pp. 223-241
Closed Access | Times Cited: 60
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 29
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 21
Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors
Xin Chen, Shuang Zhao, Hongmei Li, et al.
European Journal of Medicinal Chemistry (2019) Vol. 168, pp. 110-122
Closed Access | Times Cited: 50
QSAR analysis of coumarin-based benzamides as histone deacetylase inhibitors using CoMFA, CoMSIA and HQSAR methods
Rahman Abdizadeh, Farzin Hadizadeh, Tooba Abdizadeh
Journal of Molecular Structure (2019) Vol. 1199, pp. 126961-126961
Closed Access | Times Cited: 47
A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles
Muhamad Mustafa, Amer Ali Abd El‐Hafeez, Dalia Abdelhamid, et al.
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113569-113569
Open Access | Times Cited: 33
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
Ekta Shirbhate, Vaibhav Singh, Varsha Jahoriya, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115938-115938
Closed Access | Times Cited: 15
Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies
Abdusaid Saidahmatov, Jianan Li, Shihao Xu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15220-15245
Closed Access | Times Cited: 5
Probing into the plasma stability and microsomal stability of thiol-based prodrug derivatives: Using IYS-15, an HDAC inhibitor as the model thiol
Lingxuan Zhu, Zhiyuan Wang, Qingjiao Li, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 119, pp. 118064-118064
Closed Access
Design, synthesis and biological evaluation of novel hydroxamic acid-derived histone deacetylase inhibitors bearing a 2-oxoindoline scaffold as potential antitumor agents
Trần Thị Lan Hương, Hwa Kyung Kim, Nguyen Duc Thien, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118143-118143
Closed Access
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Liwen Xia, Meng-Yu Ba, Wei Liu, et al.
Future Medicinal Chemistry (2019) Vol. 11, Iss. 22, pp. 2919-2973
Closed Access | Times Cited: 39
Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening
Jian Liu, Jingxian Zhou, Feng-Jun He, et al.
European Journal of Medicinal Chemistry (2020) Vol. 192, pp. 112189-112189
Closed Access | Times Cited: 35
Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity
Chunhui Cheng, Yun Fan, Sadeeq Ullah, et al.
European Journal of Medicinal Chemistry (2020) Vol. 189, pp. 112073-112073
Closed Access | Times Cited: 34
Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus
Natália Lourenço de Freitas, Maria Gabriela Deberaldini, Diana Gomes, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 8
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top